×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
IMUX – immunic, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
IMUX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/26
02:09 pm
imux
Immunic (NASDAQ:IMUX) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
Medium
Report
Immunic (NASDAQ:IMUX) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
11/26
07:10 am
imux
Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December [Yahoo! Finance]
Low
Report
Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December [Yahoo! Finance]
11/26
06:30 am
imux
Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December
Low
Report
Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December
11/21
05:31 am
imux
Immunic (NASDAQ:IMUX) was upgraded by analysts at Chardan Capital to a "strong-buy" rating.
Low
Report
Immunic (NASDAQ:IMUX) was upgraded by analysts at Chardan Capital to a "strong-buy" rating.
11/14
08:09 am
imux
Immunic (NASDAQ:IMUX) had its price target lowered by analysts at HC Wainwright from $10.00 to $8.00. They now have a "buy" rating on the stock.
Medium
Report
Immunic (NASDAQ:IMUX) had its price target lowered by analysts at HC Wainwright from $10.00 to $8.00. They now have a "buy" rating on the stock.
11/13
09:01 am
imux
Immunic (NASDAQ:IMUX) had its price target lowered by analysts at D. Boral Capital from $10.00 to $8.00. They now have a "buy" rating on the stock.
Medium
Report
Immunic (NASDAQ:IMUX) had its price target lowered by analysts at D. Boral Capital from $10.00 to $8.00. They now have a "buy" rating on the stock.
11/13
06:30 am
imux
Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Medium
Report
Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
11/7
08:45 am
imux
Immunic (NASDAQ:IMUX) is now covered by analysts at Roth Capital. They set a "buy" rating and a $3.00 price target on the stock.
Low
Report
Immunic (NASDAQ:IMUX) is now covered by analysts at Roth Capital. They set a "buy" rating and a $3.00 price target on the stock.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/14
08:04 pm
imux
Form SCHEDULE 13G/A IMMUNIC, INC. Filed by: Alyeska Investment Group, L.P.
Medium
Report
Form SCHEDULE 13G/A IMMUNIC, INC. Filed by: Alyeska Investment Group, L.P.
11/14
01:40 pm
imux
Form SCHEDULE 13G/A IMMUNIC, INC. Filed by: Avidity Partners Management LP
Low
Report
Form SCHEDULE 13G/A IMMUNIC, INC. Filed by: Avidity Partners Management LP
11/13
07:27 am
imux
Form 8-K IMMUNIC, INC. For: Nov 13
Medium
Report
Form 8-K IMMUNIC, INC. For: Nov 13
11/13
07:17 am
imux
Form 10-Q IMMUNIC, INC. For: Sep 30
Medium
Report
Form 10-Q IMMUNIC, INC. For: Sep 30
11/7
04:00 pm
imux
Form SCHEDULE 13G/A IMMUNIC, INC. Filed by: Soleus Private Equity Fund III, L.P.
Medium
Report
Form SCHEDULE 13G/A IMMUNIC, INC. Filed by: Soleus Private Equity Fund III, L.P.
9/25
07:01 am
imux
Form 8-K IMMUNIC, INC. For: Sep 25
Low
Report
Form 8-K IMMUNIC, INC. For: Sep 25
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
6/24
Immunic, Inc. to Present Previously Unpublished Data Regarding Lead Program, IMU-838, at the GI Inflammatory Diseases Summit in Boston
90.9%
4/21 Immunic, Inc. Reports that IMU-838, a Selective Oral DHODH Inhibitor, Has Demonstrated Preclinical Activity Against SARS-CoV-2 and Explores Plans for a Phase 2 Clinical Trial in COVID-19 Patients 26.9%
3/25 Immunic (NASDAQ: IMUX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 26.7%
3/16 Immunic, Inc. Reports Year End 2019 Financial Results and Highlights Recent Achievements 24.4%
12/11 Immunic (NASDAQ: IMUX) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 22.8%
7/17 Form 8-K IMMUNIC, INC. For: Jul 15 12.0%
7/30 Immunic, Inc. to Present at the Canaccord Genuity 39th Annual Growth Conference on August 8 10.7%
6/4 Immunic, Inc. to Present Newly Available Preclinical Data for IMU-935 in Poster Presentation at the 2n? Conference on Molecular Mechanisms of Inflammation in Trondheim, Norway 10.2%
4/20 Form 8-K IMMUNIC, INC. For: Apr 17 9.5%
2/1 Immunic (NASDAQ: IMUX) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 7.3%
4/21 Immunic, Inc. Reports that IMU-838, a Selective Oral DHODH Inhibitor, Has Demonstrated Preclinical Activity Against SARS-CoV-2 and Explores Plans for a Phase 2 Clinical Trial in COVID-19 Patients 26.9%
3/25 Immunic (NASDAQ: IMUX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 26.7%
3/16 Immunic, Inc. Reports Year End 2019 Financial Results and Highlights Recent Achievements 24.4%
12/11 Immunic (NASDAQ: IMUX) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 22.8%
7/17 Form 8-K IMMUNIC, INC. For: Jul 15 12.0%
7/30 Immunic, Inc. to Present at the Canaccord Genuity 39th Annual Growth Conference on August 8 10.7%
6/4 Immunic, Inc. to Present Newly Available Preclinical Data for IMU-935 in Poster Presentation at the 2n? Conference on Molecular Mechanisms of Inflammation in Trondheim, Norway 10.2%
4/20 Form 8-K IMMUNIC, INC. For: Apr 17 9.5%
2/1 Immunic (NASDAQ: IMUX) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 7.3%
TOP News Decliners
3/25
Immunic and Cytosorbents among healthcare gainers; Immutep tops the losers [Seeking Alpha]
-25.6%
7/11 Immunic (NASDAQ: IMUX) is now covered by analysts at Chardan Capital. They set a "buy" rating and a $40.00 price target on the stock. -20.1%
4/21 Immunic up 16% after hours on potential COVID-19 drug [Seeking Alpha] -16.5%
4/30 Form 4 IMMUNIC, INC. For: Apr 29 Filed by: Whaley Glenn -15.9%
4/22 Form 8-K IMMUNIC, INC. For: Apr 21 -13.8%
9/5 Immunic up 26% after hours on encouraging IMU-838 data [Seeking Alpha] -12.2%
7/16 Immunic, Inc. Appoints Sanjay S. Patel, CFA, as Chief Financial Officer -12.0%
9/20 Form S-8 IMMUNIC, INC. -11.7%
11/19 Immunic, Inc. Expands Board of Directors with Appointment of Biotechnology Executive Barclay A. Phillips -10.0%
1/7 Immunic (NASDAQ: IMUX) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -9.0%
7/11 Immunic (NASDAQ: IMUX) is now covered by analysts at Chardan Capital. They set a "buy" rating and a $40.00 price target on the stock. -20.1%
4/21 Immunic up 16% after hours on potential COVID-19 drug [Seeking Alpha] -16.5%
4/30 Form 4 IMMUNIC, INC. For: Apr 29 Filed by: Whaley Glenn -15.9%
4/22 Form 8-K IMMUNIC, INC. For: Apr 21 -13.8%
9/5 Immunic up 26% after hours on encouraging IMU-838 data [Seeking Alpha] -12.2%
7/16 Immunic, Inc. Appoints Sanjay S. Patel, CFA, as Chief Financial Officer -12.0%
9/20 Form S-8 IMMUNIC, INC. -11.7%
11/19 Immunic, Inc. Expands Board of Directors with Appointment of Biotechnology Executive Barclay A. Phillips -10.0%
1/7 Immunic (NASDAQ: IMUX) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -9.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: